Zevra drug snags first FDA approval for rare and fatal metabolic disease

The latest stories trending on MedCity News.

Editor's Pick

Top Story FDA Approval Makes a Zevra Drug the First Therapy for Rare and Fatal Metabolic Disease Zevra Therapeutics drug Miplyffa is now FDA approved for Niemann-Pick disease type C, a lysosomal storage disorder. The affirmative regulatory decision took into account additional clinical data generated since the FDA turned down a submission for the drug in 2021. Sponsored Best Practices in Achieving Revenue Cycle Excellence Presented by Greenway Health Discover the best practices in revenue cycle management to enhance financial health and streamline administrative processes in healthcare.  Learn More.

Featured News

When It Comes to AI, Rural Doctors Have FOMO — Meditech & Suki Are Teaming Up to Address This Meditech is integrating Suki's AI assistant into more than a dozen rural health systems, including St. Mary's Healthcare in New York and Decatur County Memorial Hospital in Indiana. 195 Congress Members Call for Extension of Enhanced Premium Tax Credits In two letters, U.S. representatives and senators called for an extension of the enhanced premium tax credits, which are set to expire in 2025 and have lowered costs for those purchasing coverage on the marketplace. Video: INVEST Digital Health Pitch Perfect Winner Accepting Award Active investors chose Healthy Young Minds as the Pitch Perfect winner at the INVEST Digital Health Conference in Dallas. See how the company's CEO accepted the award. From Charting to Patient Intake: The 4 Biggest Opportunities for AI in Healthcare Many are already experimenting with AI in narrow settings. But in order to expand deployment, it's important to understand the most practical AI opportunities with the greatest ROI. Here are four high-impact opportunities that can boost staff efficiency and improve the patient experience. Prostate Cancer Management – We Need Better Options for Early-Stage Disease We need to continue investing in research for early stage, localized prostate cancer, develop treatments that balance efficacy with quality-of-life considerations, ensure diverse representation in clinical trials, and listen to patients and incorporate their perspectives into treatment development and decision-making.

Resources

Debunked | No-Fluff Healthcare News Show | Presented by MedCity News | Episode 8 In this episode, we address a judge's ruling against FTC's ban on non-compete clauses in employment contracts and its implications for healthcare workers. Also, Pfizer's launch of a digital platform providing easy access to providers and medications for migraine patients and vaccine seekers. Finally, Johnson & Johnson's attempt to modify its 340B drug discount program, which offers reduced prices on outpatient medications to hospitals serving uninsured patients. Watch Now

MedCity News • PO Box 901 • New York, NY unsubscribe